Cover Image

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Background - Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tu...

Full description

Saved in:
Bibliographic Details
Main Authors: Hofmann, Lars Georg Emre (Author) , Forschner, Andrea Lydia (Author) , Loquai, Carmen (Author) , Goldinger, Simone M. (Author) , Zimmer, Lisa (Author) , Ugurel, Selma (Author) , Schmidgen, Maria Isabel (Author) , Gutzmer, Ralf (Author) , Utikal, Jochen (Author) , Göppner, Daniela (Author) , Hassel, Jessica C. (Author) , Meier, Friedegund (Author) , Tietze, Julia K. (Author) , Thomas, Ioannis (Author) , Weishaupt, Carsten (Author) , Leverkus, Martin (Author) , Wahl, Renate Ursula (Author) , Dietrich, Ursula (Author) , Garbe, Claus (Author) , Kirchberger, Michael Constantin (Author) , Eigentler, Thomas (Author) , Berking, Carola (Author) , Gesierich, Anja Heike (Author) , Krackhardt, Angela (Author) , Schadendorf, Dirk (Author) , Schuler, Gerold (Author) , Dummer, Reinhard (Author) , Heinzerling, Lucie (Author)
Format: Article (Journal)
Language:English
Published: 13 April 2016
In: European journal of cancer
Year: 2016, Volume: 60, Pages: 190-209
ISSN:1879-0852
DOI:10.1016/j.ejca.2016.02.025
Online Access:Verlag, Volltext: https://doi.org/10.1016/j.ejca.2016.02.025
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001519
Get full text
Author Notes:Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria I. Schmidgen, Ralf Gutzmer, Jochen S. Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Ioannis Thomas, Carsten Weishaupt, Martin Leverkus, Renate Wahl, Ursula Dietrich, Claus Garbe, Michael C. Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie M. Heinzerling
Description
Summary:Background - Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects affect skin, gastrointestinal tract, liver, endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential. - Methods and findings - In total, 496 patients with metastatic melanoma from 15 skin cancer centers were treated with pembrolizumab or nivolumab; 242 side-effects were described in 138 patients. In 116 of the 138 patients, side-effects affected the skin, gastrointestinal tract, liver, endocrine, and renal system. Rare side-effects included diabetes mellitus, lichen planus, and pancreas insufficiency due to pancreatitis. - Conclusion - Anti-PD1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
Item Description:Gesehen am 17.06.2019
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2016.02.025

Similar Items